Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharma Plc (NQ: JAZZ )

128.71 -0.41 (-0.32%)
Streaming Delayed Price Updated: 12:17 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 163,069
Open 129.66
Bid (Size) 128.61 (4)
Ask (Size) 128.78 (2)
Prev. Close 129.12
Today's Range 127.89 - 130.76
52wk Range 125.35 - 163.31
Shares Outstanding 62,311,104
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
FDA Presents Potential Framework For CBD, From Edibles To Delta-8, Reaffirms Congress Is In Charge
The U.S. Food and Drug Administration has not given up on regulating CBD and hemp-derived products in a way that would be safe for consumers and producers. 
Via Benzinga

Performance

YTD
-17.68%
-17.68%
1 Month
-6.08%
-6.08%
3 Month
-10.83%
-10.83%
6 Month
-17.78%
-17.78%
1 Year
-12.77%
-12.77%

More News

Read More
Ford To Rally Around 33%? Here Are 10 Other Analyst Forecasts For Tuesday
Via Benzinga
Jazz Pharmaceuticals Analysis Reveals THC And CBD Therapy Alleviates MS Spasticity
Via Benzinga
Where Jazz Pharmaceuticals Stands With Analysts
Via Benzinga
Recap: Jazz Pharmaceuticals Q1 Earnings
Via Benzinga
Why Avadel Pharma Shares Are Gaining Today
Via Benzinga
World-First Clinical Trial Using Cannabis-Based Drug To Treat Deadly Brain Tumors Recruits First Patients
Via Benzinga
Jazz Pharma Q1 FY23 Revenue Grows 10% YoY, What About Net Income?
Via Benzinga
Axsome's New Drug Is Scoring a Win. Is the Stock a Buy?
Via The Motley Fool
GlycoMimetics: A Breakthrough In Hematopoietic Stem Cell Transplantation
Via Talk Markets
Pressure BioScience's Pressure-Based Tech Is Ready To Spur Innovation And Growth In A Life Sciences Sector In Flux
Via Benzinga
Why Shares of Avadel Soared This Week
Via The Motley Fool
If You Invested $5,000 in Axsome Therapeutics 5 Years Ago, Here's How Much You Would Have Now
Via The Motley Fool
The Top Healthcare Stocks to Buy With $100
Via The Motley Fool
The Global Cannabis Pharmaceuticals Market Size Is Expected To Surpass $125 Billion by 2028
Via FinancialNewsMedia
Topics Cannabis
Exposures COVID-19 Cannabis
2 Top Biotech Stocks to Buy in April
Via The Motley Fool
The 3 Best Growth Stocks to Buy in the Biotech Sector
Via InvestorPlace
Is Big Pharma Coming For Your Cannabis Business?
Via Benzinga
My Top Cannabis Stock to Buy in 2023 and Hold For 10 Years
Via The Motley Fool
Medical Marijuana Milestone In The UK: Celadon Pharmaceuticals Becomes First Company With License To Sell In Britain
Via Benzinga
Silicon Valley Bank Failure Is Just The Tip Of Financial Iceberg, Could Affect Unexpected Industries
Via Benzinga
Zymeworks Offers Hope for More than Just Long-Term Investors
Via MarketBeat
With Access To $20 Million In Financing, 1606 Corp Is Eyeing CBD Business Acquisitions As It Embarks On An Aggressive Growth Path
Via Benzinga
Pharma Mafia Wants To Conquer Cannabis: Can You Patent A Plant? Jazz Is Trying
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.